1. Introduction & Pathophysiology

• Definition: Neonate born to a mother with pre-existing diabetes (Type 1 or 2) or gestational diabetes (GDM).

%%{init: {
  "theme": "base",
  "themeVariables": { 
    "lineWidth": "3px", 
    "lineColor": "#2C3E50",
    "primaryColor": "#EBF5FB",
    "primaryTextColor": "#1B4F72",
    "primaryBorderColor": "#2E86C1",
    "lineColor": "#34495E"
  } 
}}%%

graph TD

subgraph Maternal_Environment ["Maternal Environment"]
    A["Maternal Uncontrolled Diabetes"] -->|"Hyperglycemia"| B("Maternal High Blood Glucose")
    M_Insulin["Maternal Insulin"] -.->|"Does NOT Cross Placenta"| C
end

B -->|"Glucose Crosses Placenta Freely"| C("Fetal Hyperglycemia")

subgraph Fetal_Environment ["Fetal Environment"]
    C -->|"Stimulates"| D("Fetal Pancreatic Beta-Cell Hyperplasia")
    D -->|"Overproduction"| E("Fetal Hyperinsulinemia")

    E -->|"Insulin = Growth Factor"| F["Macrosomia / Organomegaly"]
    F -->|"Risk of"| F1["Birth Trauma / Shoulder Dystocia"]

    E -->|"Increased Metabolic Rate"| G["Fetal Tissue Hypoxia"]
    G -->|"Increased Erythropoietin"| H["Polycythemia / Hyperviscosity"]
    H -->|"Breakdown of RBCs"| H1["Hyperbilirubinemia"]

    E -->|"Antagonizes Cortisol"| I["Delayed Surfactant Maturation"]
    I -->|"Risk of"| I1["Respiratory Distress Syndrome"]
end

subgraph Postnatal_Event ["Birth: Cord Clamping"]
    E -->|"Persistent Hyperinsulinemia"| J{"Glucose Supply Interrupted"}
    J -->|"Insulin remains High"| K["Neonatal Hypoglycemia"]
end

%% Clinical Complications Highlight Styling
classDef critical fill:#FDEDEC,stroke:#CB4335,stroke-width:3px,color:#78281F;
class K,H,F,F1,H1,I1 critical;

• Core Pathophysiology (Pedersen Hypothesis):
  • Maternal Hyperglycemia $\rightarrow$ Fetal Hyperglycemia (transplacental).
  • Fetal pancreatic $\beta$-cell hyperplasia $\rightarrow$ Fetal Hyperinsulinemia.
  • Postnatal separation from placenta $\rightarrow$ interruption of glucose supply + persistent hyperinsulinemia $\rightarrow$ Hypoglycemia.
  • Hyperinsulinemia acts as a fetal growth hormone $\rightarrow$ Macrosomia/Organomegaly.
  • Fetal metabolic demand $\rightarrow$ Intrauterine Hypoxia $\rightarrow$ increased Erythropoietin $\rightarrow$ Polycythemia.

2. Metabolic Complications

A. Neonatal Hypoglycemia (Most Common)

• Blood glucose < 40 mg/dL (plasma glucose < 45 mg/dL) irrespective of age, though operational thresholds vary.
• Onset usually within 1-2 hours of life.

• Clinical Features:
  • Often asymptomatic.
  • Neurogenic: Jitteriness, tremors, sweating, tachycardia, pallor.
  • Neuroglycopenic: Lethargy, poor suck, weak cry, apnea, cyanosis, seizures, coma.
• Management (Algorithm):
  • Asymptomatic (20–40 mg/dL): Trial of oral feeds (Breast milk preferred); recheck in 1 hour. If still <40 mg/dL $\rightarrow$ IV fluids.
  • Symptomatic or <20 mg/dL:
    • Bolus: 2 ml/kg of 10% Dextrose.
    • Maintenance: IV Glucose infusion @ 6–8 mg/kg/min.
    • Titration: Increase by 2 mg/kg/min (max 12 mg/kg/min) to maintain BGL > 50 mg/dL.

B. Hypocalcemia & Hypomagnesemia

• Neonatal Hypocalcemia Usually occurs within first 24–72 hours due to functional hypoparathyroidism and maternal hypomagnesemia.
• Hypomagnesemia: Caused by maternal renal wasting of magnesium; correlates with severity of hypocalcemia.

3. Hematological Complications

A. Polycythemia & Hyperviscosity Syndrome

• Venous hematocrit $\ge$ 65% or Hb > 22 g/dL.
• Pathophysiology: Fetal hypoxemia (placental insufficiency or high metabolic rate) $\rightarrow$ increased erythropoiesis.
• Clinical Features: CVS: Plethora (ruddy complexion), cyanosis. CNS: Lethargy, jitteriness, seizures, infarcts. Cardiopulmonary: Tachypnea, tachycardia, respiratory distress, cardiomegaly (pulmonary plethora). GI: Poor feed, vomiting, Necrotizing Enterocolitis (NEC). Renal: Oliguria, renal vein thrombosis. Metabolic: Hypoglycemia, jaundice.
• Manageed with Hydration and partial exchange traansfusion

B. Hyperbilirubinemia

• Secondary to polycythemia (increased RBC mass breakdown) and immature hepatic conjugation.

C. Thrombocytopenia

• Mild, transient; associated with polycythemia/hyperviscosity.

4. Respiratory Complications

• Respiratory Distress Syndrome (RDS): Delayed surfactant maturation due to antagonism of cortisol by insulin.
• Transient Tachypnea of Newborn (TTN): Common in infants delivered via elective CS (associated with macrosomia).

5. Congenital Anomalies (Embryopathy)

• Occurs due to hyperglycemia during organogenesis (First Trimester).
• Cardiac: Hypertrophic Cardiomyopathy (septal hypertrophy - transient), Transposition of Great Arteries (TGA), VSD.
• CNS: Neural tube defects, Anencephaly.
• Skeletal: Caudal Regression Syndrome (Sacral Agenesis) – most specific to IDM.
• Gastrointestinal: Small Left Colon Syndrome, Situs Inversus.
• Renal: Renal vein thrombosis (associated with polycythemia).

6. Growth Abnormalities

• Macrosomia (LGA): Birth weight > 90th percentile or > 4000g. Risk of birth trauma (shoulder dystocia, Erb’s palsy, clavicle fracture) and asphyxia.
• IUGR (SGA): Seen in mothers with severe diabetic vasculopathy (placental insufficiency).

7. Long-term Outcome

• Neurodevelopment:
  • Symptomatic hypoglycemia linked to white matter abnormalities and executive function deficits.
  • Polycythemia-associated hyperviscosity may cause micro-infarcts but PET benefits on long-term outcome are debated.
• Metabolic: Increased risk of childhood obesity and early-onset Type 2 Diabetes (Metabolic programming).